| 26.72 -1.19 (-4.26%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.39 | 1-year : | 39 |
| Resists | First : | 28.59 | Second : | 33.39 |
| Pivot price | 26.86  |
|||
| Supports | First : | 25.77 | Second : | 24.03 |
| MAs | MA(5) : | 27.13 |
MA(20) : | 26.58 |
| MA(100) : | 23.22 |
MA(250) : | 22.87 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 76.3 |
D(3) : | 76.4 |
| RSI | RSI(14): 53.5 |
|||
| 52-week | High : | 29.37 | Low : | 14.39 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CLDX ] has closed above bottom band by 43.4%. Bollinger Bands are 34.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.22 - 28.36 | 28.36 - 28.47 |
| Low: | 26.23 - 26.37 | 26.37 - 26.48 |
| Close: | 26.49 - 26.73 | 26.73 - 26.92 |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Thu, 23 Oct 2025
Celldex Therapeutics (CLDX): Evaluating Valuation After Barclays' Underweight Rating and Industry Concerns - Yahoo Finance
Tue, 21 Oct 2025
Mizuho Initiates Coverage of Celldex Therapeutics (CLDX) with Outperform Recommendation - Nasdaq
Tue, 21 Oct 2025
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: A Deep Dive Into Its 93% Upside Potential - DirectorsTalk Interviews
Mon, 20 Oct 2025
Barclays Initiates Coverage of Celldex Therapeutics (CLDX) With an Underweight Rating - Insider Monkey
Wed, 15 Oct 2025
Celldex Therapeutics (CLDX): Assessing Valuation as Barzolvolimab Hype and Biotech Optimism Drive Renewed Investor Focus - simplywall.st
Wed, 15 Oct 2025
Celldex Therapeutics (CLDX): Assessing Valuation as Barzolvolimab Hype and Biotech Optimism Drive Renewed Investor Focus - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 5.321e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 7,210 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.314e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 747.5 % |
| Return on Equity (ttm) | -19.1 % |
| Qtrly Rev. Growth | 5.79e+006 % |
| Gross Profit (p.s.) | -53.24 |
| Sales Per Share | -20.44 |
| EBITDA (p.s.) | -1.45278e+008 |
| Qtrly Earnings Growth | -3.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -186 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.31 |
| Price to Cash Flow | 3.6 |
| Dividend | 0 |
| Forward Dividend | 7.08e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|